# A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer

> **NCT02608073** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 45 (actual)

## Conditions studied

- Nasopharyngeal Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02608073
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2016-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02608073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02608073, "A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02608073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*